Get the latest news on Strategy Shares Nasdaq 7HANDL Index ETF stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on HNDL performance

Latest Strategy Shares Nasdaq 7HANDL Index ETF  News | NASDAQ:HNDL | Benzinga

Strategy Shares Nasdaq 7HANDL Index ETF

Technology

Energy

Financial Services

Real Estate

Consumer Cyclical

Healthcare

Industrials

Consumer Defensive

Utilities

Communication Services

Basic Materials

Other

The fund will invest at least 80% of its assets in securities of the NASDAQ 7 HANDL Index (the index). The index consists of securities issued by exchange-traded funds and is split into two components, with a 50% allocation to fixed income and equity ETFs (the Core Portfolio) and a 50% allocation to ETFs of 12 asset categories (the Explore Portfolio).

Ishares Core U.s. Aggregate

Vanguard Total Bond Market ETF

Spdr Portfolio Aggregate Bond Etf

Alerian Mlp ETF

Invesco Nasdaq 100 ETF

Wisdom Tree US Efficient

Vanguard Dividend Apprec

Jpm Eqty P-Inc

Xtrackers USD High Yield Corporate Bond ETF

Schwab US Reit ETF

Strategy Shares Nasdaq 7 HANDL Index ETF

News

Guidance

ADSK

Autodesk Sees Q1 2026 Revenue $1.6B-$1.61B Vs $1.598B Estimate; Sees Adj. EPS $2.14-$2.17 Vs $1.87 Estimate

Earnings

ACLX

Arcellx FY 2024 GAAP EPS $(2.00) Misses $(1.66) Estimate, Sales $107.936M Miss $121.765M Estimate

Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) reported quarterly sales of $209.60 million which beat the analyst consensus estimate of $205.40 million by 2.04 percent. This is a 38.82 percent increase over sales of $150.99 million the same period last year.

Earnings Beats

DUOL

Duolingo Q4 Sales $209.60M Beat $205.40M Estimate

CYTK

Cytokinetics Sees FY25 GAAP Operating Expense $670M-$710M

NTAP

RDFN

CORRECTION: NetApp Sees Q4 Adj. EPS $1.84-$1.94 vs $1.99 Est., Net Revenues $1.65B-$1.8B vs $1.763B Est.; Sees FY25 Adj. EPS $7.17-$7.27 vs $7.32 Est., Net Revenues $6.49B-$6.64B vs $6.656B Est.

Data I/O (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAIO#NASDAQ">DAIO</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.03) by 333.33 percent. This is a 750 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $5.18 million which missed the analyst consensus estimate of $5.75 million by 9.81 percent. This is a 24.57 percent decrease over sales of $6.87 million the same period last year.

Earnings Misses

DAIO

Data I/O Q4 EPS $(0.13) Misses $(0.03) Estimate, Sales $5.18M Miss $5.75M Estimate

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.27) by 3.7 percent. This is a 42.22 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $73.700 million which beat the analyst consensus estimate of $72.393 million by 1.81 percent. This is a 15.19K percent increase over sales of $482.000 thousand the same period last year.

IOVA

Iovance Biotherapeutics Q4 2024 GAAP EPS $(0.26) Beats $(0.27) Estimate, Sales $73.700M Beat $72.393M Estimate

Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.17) by 7.69 percent. This is a 8.7 percent increase over losses of $(1.38) per share from the same period last year. The company reported quarterly sales of $16.927 million which beat the analyst consensus estimate of $1.742 million by 871.94 percent. This is a 912.38 percent increase over sales of $1.672 million the same period last year.

Cytokinetics Q4 2024 GAAP EPS $(1.26) Misses $(1.17) Estimate, Sales $16.927M Beat $1.742M Estimate

Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) sees Q1 sales of $17.000 million-$18.000 million vs $16.27 million analyst estimate.

PSNL

Personalis Sees Q1 Sales $17.000M-$18.000M vs $16.27M Est

ARB IOT Group Limited ("ARB IOT" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) has, through its indirect wholly owned subsidiary, ARB IOT Group Sdn Bhd, signed a Memorandum of Understanding ("MOU") to set up an AI data centre experimental laboratory, a state-of-the-art facility designed for advanced research and AI application development. This initiative is in partnership with a UKM startup (the "UKM Startup") affiliated with the Institute of Visual Informatics of Universiti Kebangsaan Malaysia, a leading research university in Malaysia ("IVI-UKM"), and Gajah Kapitalan Sdn Bhd ("GKSB").
The AI data centre experimental laboratory facility aims to create a dedicated environment for advancing AI research, AI application development, testing and deployment. It provides state-of-the-art infrastructure and resources to foster innovation, collaboration and skill building in AI technologies. The AI data centre experimental lab will boast AI servers of ARB 222 and ARB 333 series and will be located at IVI, UKM, Malaysia.
The ARB-222 and ARB-333 series are high-performance rackmount servers designed for AI, deep learning, and enterprise computing. These AI servers are optimized for AI inference and data processing while also excelling in fine-tuning AI training and handling large-scale simulations. Built for reliability and scalability, these servers offer greater energy efficiency compared to other AI products available in the market.
This initiative aligns with the Malaysian government's initiatives to strengthen AI capabilities at the regional and national level and to encourage and nurture more data scientists and engineers to participate in the robust AI development and data science community.
This MOU represents a strong commitment to robust collaboration in exchanging knowledge and expertise in the AI industry.&nbsp; Under the MOU, the Company will be responsible for the architecture and design of the laboratory facility.
Bridging the gap between research and practical applications, this initiative brings together the academia and industry partners to fast-track the adoption of innovative and sustainable AI server solutions. These collaborative efforts will set new sustainability standards for AI data centre operations in the region. This is a significant milestone to drive innovation and deliver value to the customers, partners and the nation.
By having an AI data centre experimental lab with the AI servers of ARB 222 and ARB 333 series in the region, the Company is well positioned to capture a significant growth portion of AI-driven economy in the future.
This MOU marks a significant milestone in the Company's growth, leveraging combined expertise in AI computing technology and promoting sustainable advanced AI server solutions to accelerate the AI revolution in the region.

ARBB

ARB IOT Group Announces Entry Into A MOU to Set-Up AI Data Centre Experimental Laboratory In The Region

Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) sees FY2025 sales of $80.000 million-$90.000 million vs $84.65 million analyst estimate.

Personalis Sees FY2025 Sales $80.000M-$90.000M vs $84.65M Est

Rimini Street (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMNI#NASDAQ">RMNI</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05 by 40 percent. The company reported quarterly sales of $114.200 million which beat the analyst consensus estimate of $102.507 million by 11.41 percent. This is a 1.86 percent increase over sales of $112.111 million the same period last year.

RMNI

Rimini Street Q4 2024 GAAP EPS $0.07 Beats $0.05 Estimate, Sales $114.200M Beat $102.507M Estimate

Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 17.86 percent. This is a 57.41 percent increase over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $16.80 million which beat the analyst consensus estimate of $15.74 million by 6.75 percent. This is a 14.61 percent decrease over sales of $19.68 million the same period last year.

Personalis Q4 EPS $(0.23) Beats $(0.28) Estimate, Sales $16.80M Beat $15.74M Estimate

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) affirms FY2025 sales outlook from $735.00 million-$750.00 million to $735.00 million-$750.00 million vs $740.46 million estimate.

COLL

Collegium Pharmaceutical Affirms FY2025 Sales Guidance of $735.00M-$750.00M vs $740.46M Est

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $2.14 by 7.01 percent. This is a 9.57 percent increase over earnings of $2.09 per share from the same period last year. The company reported quarterly sales of $1.64 billion which beat the analyst consensus estimate of $1.63 billion by 0.52 percent. This is a 11.64 percent increase over sales of $1.47 billion the same period last year.

Autodesk Q4 2025 Adj EPS $2.29 Beats $2.14 Estimate, Sales $1.64B Beat $1.63B Estimate

Outlook for First Quarter and Fiscal Year 2025
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2">Three Months Ending March 31, 2025</td>
<td colspan="2">Twelve Months Ending December 31, 2025</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>$ Millions</td>
<td colspan="1">Low</td>
<td colspan="1">High</td>
<td colspan="1">Low</td>
<td colspan="1">High</td>
</tr>
<tr>
<td>Health Plan Membership</td>
<td>211,000</td>
<td>215,000</td>
<td>227,000</td>
<td>233,000</td>
</tr>
<tr>
<td>Revenue</td>
<td colspan="1">$880</td>
<td colspan="1">$895</td>
<td colspan="1">$3,720</td>
<td colspan="1">$3,775</td>
</tr>
<tr>
<td>Adjusted Gross Profit(1)</td>
<td colspan="1">$89</td>
<td colspan="1">$97</td>
<td colspan="1">$415</td>
<td colspan="1">$445</td>
</tr>
<tr>
<td>Adjusted EBITDA(2)</td>
<td colspan="1">$2</td>
<td colspan="1">$10</td>
<td colspan="1">$35</td>
<td colspan="1">$60</td>
</tr>
</tbody>
</table>
</figure>

ALHC

Alignment Healthcare Sees Q1 Revenue $880M-$895M Vs $855.745M Est.; FY25 Revenue $3.72B-$3.775B Vs $3.476B Est.

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.86) by 2.33 percent. This is a 31.25 percent decrease over losses of $(0.64) per share from the same period last year.

XENE

Xenon Pharmaceuticals Q4 2024 GAAP EPS $(0.84) Beats $(0.86) Estimate

Stifel initiated coverage on Compass Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>), saying, &#8220;The Time Is <a href="https://www.benzinga.com/markets/psychedelics" target="_blank" rel="noreferrer noopener">Now for Psychedelics</a>.&#8221;
Compass is a clinical-stage biotechnology company focused on developing psychedelics-based drugs for neuropsychiatric disorders.
The analyst equates COMP360 to Spravato 2.0. Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Spravato (esketamine)&nbsp;is a nasal spray for TRD and major depressive disorder (MDD), selling over ~$1 billion annually.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/42173279/compass-pathways-institutional-pressure-amid-43m-market-cap-decline-whats-next-for-this-psychedelics-co" rel="noreferrer noopener">COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What&#8217;s Next For This Psychedelics Co?</a>
Stifel writes, &#8220;commercial success of Spravato offers major validation that the intermittent psychedelic treatment model for depression is scalable.&#8221;
Stifel has initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/CMPS/analyst-ratings" rel="noreferrer noopener">price target of $11</a>. Analyst Paul Matteis expects the company to be well positioned over the next ~18 months to derisk COMP360 (psilocybin) in two phase 3 studies. COMP360 doesn&#8217;t need to be a blockbuster to garner meaningful upside to the stock.
The company says the pivotal phase 3 program of COMP360 psilocybin treatment in treatment-resistant depression (TRD) is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted.
Top-line 6-week (primary endpoint) COMP005 data is on track for the second quarter of 2025, and 26-week COMP005 data is expected in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44001614/compass-pathways-announces-fourth-quarter-and-full-year-2024-financial-results-and-business-highli" rel="noreferrer noopener">second half of 2026</a>.
In addition, the design of a late-stage clinical program for patients with post-traumatic stress disorder is underway.
Stifel analyst says Compass Pathways was once a hyped early-stage IPO in 2020, fueled by excitement around psychedelics. Now, it has established itself as a &#8216;credible CNS biotechnology company.&#8217;
About five years ago, psychedelics gained attention, but many uncertainties remained. While some investors still have concerns, Compass has made significant progress.
The company has strengthened its leadership team, reduced risks for psilocybin-based therapy (COMP360) through a well-controlled trial published in NEJM, and aligned its Phase 3 program with FDA standards.
Compass Pathways says the $165.1 million cash position&nbsp;is expected to fund operating expenses and capital expenditure requirements at least through the planned 26-week data read-out <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44001614/compass-pathways-announces-fourth-quarter-and-full-year-2024-financial-results-and-business-highli" rel="noreferrer noopener">from the COMP006 study</a>.
Price Action: CMPS stock is up 6.22% at $3.93 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44007299/warner-bros-q4-earnings" target="_blank" rel="noreferrer noopener">Warner Bros Q4 Earnings: Studios Revenues Grow 16%, Max Subscribers Surge, Eyes 150 Million Subscribers By 2026</a></li>
</ul>
Photo by Zita and canadastock via Shutterstock.

Analyst Color

Cannabis

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

CMPS

Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) reported quarterly earnings of $1.75 per share which beat the analyst consensus estimate of $1.54 by 13.64 percent. This is a 10.76 percent increase over earnings of $1.58 per share from the same period last year. The company reported quarterly sales of $181.95 million which beat the analyst consensus estimate of $179.79 million by 1.20 percent. This is a 21.51 percent increase over sales of $149.75 million the same period last year.

Collegium Pharmaceutical Q4 Adj EPS $1.75 Beats $1.54 Estimate, Sales $181.95M Beat $179.79M Estimate

NetApp Q3 2025 Adj. EPS $1.91, Inline, Sales $1.641B Miss $1.695B Estimate

Comments

Strategy Shares Nasdaq 7HANDL Index ETF Stock News

News

Latest Strategy Shares Nasdaq 7HANDL Index ETF News | NASDAQ:HNDL | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga